Several prescription digital therapeutics companies have entered the market with genuinely strong randomized controlled trial evidence, FDA marketing authorization, and clear clinical need — only to struggle commercially or shut down entirely. The pattern has repeated often enough that it points to a structural problem, not simply individual company execution failures: the reimbursement infrastructure for digital therapeutics has consistently lagged well behind the clinical evidence supporting them.
Why DTx Doesn't Fit Existing Reimbursement Categories
The U.S. healthcare reimbursement system evolved around a few well-established categories: pharmacy benefits for drugs, medical benefits for procedures and devices, and behavioral health benefits for counseling services. A prescription digital therapeutic doesn't map cleanly onto any of these. It's prescribed like a drug but isn't dispensed through a traditional pharmacy. It's software, but it's not a durable medical equipment purchase. It delivers a therapeutic intervention, but it's not a billable in-person service. This categorical ambiguity has meant payers frequently lack a clear billing code or coverage policy to process a DTx claim at all, regardless of the clinical evidence behind it.
The CPT Code Gap
Billing infrastructure depends heavily on Current Procedural Terminology (CPT) codes, and for years no dedicated CPT code category existed for digital therapeutics specifically. The American Medical Association has since introduced specific CPT codes for digital therapeutic treatment management, a necessary but not sufficient step — a billing code existing doesn't guarantee a payer will assign it a reimbursement rate that makes the underlying business sustainable for the DTx company providing the service.
The Employer Benefits Workaround
In the absence of consistent traditional insurance coverage, several DTx companies pivoted toward selling directly to self-insured employers as part of broader digital health benefit packages, betting that employers motivated by reduced downstream healthcare costs and improved employee productivity would move faster than traditional payers. This channel has provided meaningful revenue for some companies, though it creates a fragmented, employer-by-employer sales motion that's expensive to sustain and doesn't reach patients whose employers haven't adopted the relevant benefit.
State Medicaid Movement
Some states have moved to explicitly add digital therapeutics to their Medicaid preferred drug lists or formularies, treating a DTx more like a pharmacy benefit than payers have historically been willing to do — a meaningful policy signal given Medicaid's role in covering populations with high rates of the chronic conditions (substance use disorder, diabetes, certain mental health conditions) where DTx evidence is strongest.
What Would Actually Fix the Problem
Industry groups have consistently pushed for federal legislation establishing a permanent, predictable reimbursement pathway for FDA-authorized digital therapeutics, analogous to the way the pharmacy benefit provides predictable reimbursement for approved drugs. Absent that structural fix, individual payer-by-payer and employer-by-employer coverage decisions will likely continue to determine which patients can actually access DTx that their physician might otherwise prescribe.
Conclusion
The digital therapeutics field has largely solved the harder problem — generating genuine clinical trial evidence for software-delivered treatment. The remaining challenge is administrative and political rather than scientific: building a reimbursement infrastructure that lets that evidence translate into patient access at scale.
